Precipio, Inc. (PRPO) Earnings Call Transcript
November 10, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for being with us. Before we move into reviewing the Q3 2026 results and sharing a few thoughts about 2027, I figured that since we're wrapping up another successful year, it could be useful to bring one more member of the management team onto these calls. I'd like to introduce my Co-Founder and Precipio's Chief Operating Officer, Zaki Sabet. Dr. Ayman Mohamed and I, the three of us, launched Precipio back in 2011, and we've been inseparable ever since. Before Precipio was founded, Zaki built his career in the diagnostics industry. During his college years, Zaki worked the night shift as an accessioner at a lab in New Jersey, and over the years he climbed through the ranks from lab tech to supervisor and ultimately to managing the whole laboratory. Bringing deep expertise, Zaki was the one responsible for building what is today, to the best of our knowledge, at our size, one of the few profitable hematopathology laboratories in the country. At Precipio, Zaki is in charge of all company operations, covering both our clinical laboratory and operations for the Products Division, including manufacturing and supply chain. Today, Zaki will join me in sharing some remarks, and he'll also be around to take questions during the Q&A section. Since this is our last scheduled shareholder call of 2026, I'd like to frame these results against the progress we've made over the past couple of years and explain how that progress sets the stage for 2027. In 2025, our focus was on getting the company to a cash flow positive position. We'd been through several dilutive financings and decided it was time for the company to stand on its own two feet and become financially independent. We set our eyes on reaching cash flow positive through a combination of revenue growth alongside significant operational efficiency improvements. At the end of 2025, we were there. Our company was cash flow positive, no longer dependent on outside capital in order to survive, and for the first time, we were able to respond to the calls from the various investment banks and hedge funds looking to provide capital to Precipio with a polite but clear, "No, thank you." I can tell you, as the person responsible for raising money to keep the lights on for 15 years, that was a wonderful moment. The second goal in 2025 was to determine if the products we created and that were used in our own lab would be real value to other laboratories. We carefully explored this market by identifying target customers in several segments, which would serve as an indicator of market interest; this meant reaching a better understanding of which products in which configuration suited each segment. It meant continuously refining our sales presentation and value proposition to give the customer what they wanted, and also to determine which level of support was required by each customer. Although a lot of investors noticed that our revenue stayed fairly flat in 2025, the learning we gained from that experience was essential at the time, and it gives us a strong foundation for deciding how our sales team should target the market efficiently, how our R&D team should build the right product, and how our support team should be properly equipped to onboard customers. By the close of 2025, we had completed two key tasks. The first was financial independence, and the second was a market understanding of our customers along with our value proposition. In 2026, armed with a clearer grasp of our customer base, our product mix, and the best ways to serve our customer, we set out to validate our go-to-market strategy by reaching customers through distribution. Something we learned in 2025 and earlier was that within the laboratory space, getting in front of the customer and meeting the right decision-makers is genuinely hard. After COVID, without a personal relationship, it was almost impossible. We also learned that once we stood in front of the decision-maker, we were quite successful at closing the sale. So how do we get that door opened for us? Distributors play an important role in this field. Through working with the industry's top four distributors, Thermo Fisher, Medline, McKesson, and Cardinal Health, we have come to understand the power of the 200-plus sales reps that each of these distributors employs. These are armies of well-trained, experienced, and well-connected reps who have long-established relationships with their customers, often spanning 10 to 15 years. No amount of money would let us replicate even a fraction of that sales force power, so we decided distribution was the way to go. We also learned that every distributor is different, with differing organizational structures, differing division of responsibilities among reps, and differing organizational cultures that dictate how best to interact with each distributor; in 2026, we set out to figure out the recipe for success with each one. Along the way, we also learned which internal skill sets we needed to develop inside our commercial team so we could best apply each recipe with each distributor. As we stand now at the end of 2026, we feel we have figured out most of what we set out to discover regarding the recipe with each distributor. That has led to some new hires on our commercial team and to a clear internal articulation of our go-to-market strategy through distribution. You have seen the Products Division grow gradually over the first three quarters of this year. While seeing the business grow is always nice, this is by no means satisfactory to us, nor does it reflect our planned growth trajectory going forward. Quite the opposite. 2027 will mark an important next phase in Precipio's evolution as we shift our focus from developing and validating our commercial strategy to accelerated growth. With the right products, a clear grasp of who our target customers are, a distribution strategy that's already established, and the commercial infrastructure we're building out, we believe the foundation is now in place to go after a much higher growth rate in our product business. For the first time, we want to give shareholders some specific financial objectives that we plan to use in measuring our progress; for our Products Division, the target is an annual revenue run rate above $10 million by the end of 2027, versus roughly $4 million annualized run rate derived from our third quarter results of 2026. Our Pathology Services business will also stay an important piece of our growth strategy. Beyond the role it plays in supporting product development and clinical validation, it keeps generating most of our operating cash flow. We plan to keep growing this business, with a target of an annualized revenue run rate of about $30 million by the end of 2027. Taken together, these objectives amount to a combined annualized revenue run rate above $40 million by the end of 2027. To be clear, these are targets for the annualized revenue run rate we aim to hit as we exit 2027, not a forecast of total revenue recognized during the year.
We believe that reaching these objectives would represent a significant leap for Precipio, demonstrating that our product business is capable of scaling while strengthening the financial foundation that allows us to fund ongoing growth, product innovation, and entry into new diagnostic markets. These targets are ambitious, we recognize, and achieving them will require disciplined execution, yet in our view the progress achieved across the past two years positions us favorably for this next phase of growth. Now let's turn to Q3. Total revenue climbed from about $7 million in Q2 to $7.2 million in Q3. Pathology revenue was approximately $6.3 million, while product revenue exceeded $1 million in a single quarter for the first time, an exciting milestone. Adjusted EBITDA came to roughly $400,000, consistent with Q2. Operating cash flow was around $600,000, compared with approximately $700,000 in the second quarter. Overall cash rose by roughly $0.5 million in Q3, raising our quarter-end cash balance to more than $3.5 million versus about $2.2 million a year earlier. With these results we now have a sturdier financial footing; having gained the confidence of a business that reliably produces cash flow, the moment has arrived to shift the balance. While remaining cash flow positive, we plan to direct our focus toward substantially accelerated revenue growth. Let's discuss how we intend to scale up for growth on the product side. 2026 was all about learning the recipe for growth. As we've discussed, we regard distribution as the primary source of scalability for our Products Division, and we wanted to learn how to make that channel work best before committing resources to wider commercial expansion. We deliberately pursued this with a fairly small commercial team and a restrained level of spending. We wanted to hone the distributor model and our overall sales strategy before building a bigger sales and marketing effort around them. The order was deliberate: establish the approach, learn from execution, and then invest in scaling it; we now believe we understand that recipe, and how to support it, much more clearly. Our ability to engage effectively with distributor reps, equip them with information to secure us a meeting, and then build a pipeline gives us confidence that we are ready for the next stage. The time has now come to shift our emphasis from developing the model and understanding the recipe toward implementing and extending its reach; in 2027, growth will be our central commercial priority; we intend to significantly expand the commercial team and set aggressive goals for them while increasing marketing and technical support behind our products. It is time to pour gas on the fire, using the incoming cash flow as resources toward accelerating the distributor and sales approach we spent this year developing. An important part of that plan involves bringing in a senior marketing executive to lead initiatives that were not previously pursued at this level. We want a more active market presence and a more systematic way of building awareness, credibility, and access to prospective customers, and that means a stronger showing at relevant conferences where we can engage laboratories, clinicians, and our distribution partners. It also means developing a network of key opinion leaders who can offer clinical insight and help shape the evidence required to support adoption. We intend to establish clinical credibility through additional publications and case studies that set out the application and value of our technologies. Our products need to be backed by evidence that is useful to the physicians and laboratories making testing decisions. Marketing will also collaborate closely with sales on prospecting and customer access. The aim is to pinpoint the right accounts, reach the people involved in testing decisions, and give our sales team stronger materials and more chances for substantive customer discussions. That should carry over to our distributors as well as to our direct commercial efforts. These initiatives are meant to work in tandem. Conferences generate opportunities for engagement, clinical relationships and evidence reinforce our credibility, and coordinated marketing and sales follow-up help move that interest toward evaluation and adoption. Since quarter end, we have made changes to the commercial leadership and are bringing our Products and Pathology Services sales efforts under a structure that is more coordinated. Our recent product training week brought commercial, clinical, and operational teams together to deepen product knowledge and strengthen customer conversations; these steps all support the broader growth effort we are preparing for next year; we will measure progress through customers completing implementation, beginning clinical use, and placing repeat orders, ultimately resulting in revenue growth. Aggressive goals need to translate into results, and we intend to maintain that discipline and focus as we expand our commercial activity. As we shift from developing our commercial strategy to executing against a far more ambitious growth plan, operational leadership and accountability across the whole organization will become increasingly important. Total cash rose by roughly $0.5 million during Q3, lifting our quarter end cash balance above $3.5 million compared with approximately $2.3 million a year earlier. Zaki has been instrumental in building the infrastructure that brought us to this point, so I've asked him to join this call and share his perspective on how we plan to scale the business from here. Zaki, all yours.
Thanks, Ilan, and good afternoon, everyone. As Ilan laid out, over the past several years we've been constructing the foundation for Precipio's next phase of growth. My emphasis has been on building an organization capable not only of delivering high-quality diagnostic services and products, but of doing so efficiently, profitably, and at a scale substantially larger than where we operate today. One of Precipio's greatest strengths, in my view, is the operational infrastructure we've already put in place, along with the opportunity before us now to leverage that infrastructure as the business expands. In our Pathology Services division, we've shown we can grow revenue while also improving efficiency and profitability. We've invested in our people, systems, processes, and laboratory capabilities, creating an operating model that we believe can handle substantial additional volume without needing a corresponding rise in our cost base. On the product side, we've taken that same approach. We've built manufacturing capabilities, quality systems, and technical support infrastructure designed not merely for our current level of sales, but for the far larger business we intend to build. And importantly, these two divisions are closely interconnected. Our clinical laboratory isn't just a source of revenue and cash flow. It's also where we develop, validate, and continually improve our technologies, which gives us a unique understanding of how our products perform in real-world clinical environments and what our customers need in order to implement them successfully. To put the scale of the opportunity into perspective, we estimate that our existing operational infrastructure has the capacity to support approximately $100 million in annual revenue, split roughly equally between Pathology Services and product manufacturing, without requiring significant additional capital investment in our core facilities and equipment; that represents a substantial amount of capacity relative to where our business stands today, and it creates an important opportunity for us to scale revenue, improve margins, and drive greater profitability as we grow. Back to you, Ilan.
Thank you, Zaki. To sum things up, the direction of travel is unmistakable. During 2025, our emphasis was on getting to positive cash flow and standing on our own financially; then in 2026, with cash coming in, we examined and sharpened the commercial strategy that we think can be scaled across our Products Division. Come 2027, we plan to commit substantial resources straight toward executing that commercial strategy and to concentrate fully on growth. We head into the coming year with a solid financial base and a well-defined commercial path. What lies ahead is converting that groundwork into quicker growth. I want to express appreciation to our committed employees for everything they do, and to our shareholders for the support you keep giving us. For us, 2027 will be yet another pivotal year. Zaki and I are ready now to take your questions. Thank you.
Hey, guys. How are you?
Hey, Sean.
Are you guys able to hear me fine?
Yes, we can hear you perfectly.
Okay, that sounds good. Solid quarter. I'd like to dig a bit into product sales and how scalable they are. You spent a fair amount of time on that in your remarks here. Could you give us a quick update on the sales force as it stands now — what's the headcount, and roughly how many people do you have on it? And then, you mentioned putting some of the cash flow back into that organization. Where do you see that number landing over the next year or so?
Yes, thanks. Appreciate the question. Right now our sales force numbers four, and we intend to double it in the coming year. Like I mentioned in the remarks, since we now have the recipe, we understand how to collaborate with distributors and how to move efficiently from a lead to a customer to a conversion, so this is the moment when we can scale it up. We're going to grow that considerably. We anticipate bringing on probably two more people at least by the start of the year, and then carrying on through the year to really expand it. Part of the reason is also to keep up with demand from our distributors. As our ties with them get stronger, we're seeing more and more leads, more and more prospects, more and more meetings that our team needs to handle.
Understood. Great. Regarding that sales cycle and the sales side, now that you've kind of got four in place around the ramp-up time for these new folks, do you have any sense of when they'll start ramping up enough to actually deliver some product sales?
Yeah. Unfortunately, that remains an unknown variable, and the range is pretty broad. Just as an example, we had a customer going live this quarter in Q4 that we'd probably been working on for almost a year and a half. Conversely, there was a customer we met for the first time in late September, and in fact this week they're going through training and about to start validation. They'll likely go live before the end of the year. So I'd say the two bookends of the customer onboarding timeline are probably somewhere between three months and 18 months. We've come up with ways to shorten that, and we're implementing them, but for some customers it's simply the process they have to go through, unfortunately. Now, I think the way to fix that in terms of just scaling up revenue is simply to have a large enough number so that every quarter we've got another $0.25 million, half a million dollars of new revenue coming in. That's just broad. At the end of the day, it's just shots on goal.
Right. Great. As far as gross margin goes, on the product gross margin, there are no changes there. I don't think you guys have always had pretty healthy gross margins on that. Is there anything related to the distributor impacts that would affect gross margin or anything like that?
No, not at all. That is basically the calculation. Right now we are hovering around the kind of high 40s, 50% gross margin. As we scale up, when we double our revenue, I think, I am trying to do the math in my head, but I think the margins jump to probably the mid-60s, and we will continue that way. This will, at a higher scale, it would be a good 70%, 75% gross margin.
Understood. Excellent. That's everything from my side. Thank you, everyone.
Thank you, Sean. I appreciate that.
Hey there, congratulations on a solid quarter and the product growth. During Q2, you mentioned there were more than 25 new qualified customers. Could you share any details on whether any of them have converted, and what that count looks like right now?
Let me think about Q2. I believe we've had maybe 2 or 3 go live this quarter, and a large number of them are scheduled for the first half of 2027. That's roughly the timeline. Some will land later than that. But we're seeing decent conversions and good progress across all of them as they move through onboarding and validation.
Great. Regarding that $1 million in product revenue, I noticed a footnote mentioning some project revenue in there. Is that a reasonable baseline for us to work from, with kind of sequential quarterly growth as we exit into the $10 million plus band in 2027?
Yeah, absolutely. I think the nice part here is the building blocks. Once a customer is on board, they've got X volume of patient samples that comes in fairly consistently on a quarterly basis; we expect them, and it has proven true, that for the most part they are going to have at least that much in sequential quarters. But if you usually grow from specific customers, then when they add additional panels, and usually a customer will start with one or two panels, and within six to 12 months, they will have three to four panels. So, we will see kind of organic growth within those customers as well in the revenue growth. But yeah, I think, and our numbers have shown we have had, I think only once where the revenue has dropped, and that was because of the shift, an order from one quarter to the other.
Excellent. That's everything from me. I appreciate your time, and congratulations on the quarter.
Thank you, Jack.
Hi there. Appreciate you taking my question. When you think about broadening what the product can do, are there any fresh tests or disease areas that you're sort of working on, and does that get included in the $10 million figure for next year?
Ben, thanks for asking. Right now, the pipeline we're referring to covers only those products that are already on the market today. What we intend to do is keep going with the products we currently have available. For the time being, we're largely concentrated on the heme or blood-related cancer space, until we achieve the growth we're hoping to see, and after that we'll decide whether to expand into other disease areas beyond heme and blood.
Great. That's all for me. Thank you.
Yeah.
Hi, and congratulations on the strong quarter. Let me apologize up front, since I lack the skill set that would let me work through the tax hole. What I am struggling with is the amount of sales expense you expect compared with the growth. My sense is that the existing sales staff, with distributor relationships already established, ought to be able to deliver a good share of the growth you have laid out for us. I simply do not grasp why so much extra investment on the sales side is needed to hit the targets you describe. Could you elaborate? What strikes me is that maybe some price declines are baked in and/or there are demand issues, but correct me if I am wrong. Thanks.
Hi, Vincent. Thank you for your question. No, there are no price declines or drops in demand; we have a pretty strict pricing strategy that we hold across the board with all our distributors, so we kind of stick to that, and that is locked in contractually. There is no price decline, nor is there any decrease in demand. I think as we mentioned in the conference call, we have taken a very conservative approach in terms of our sales force. I think if you compare us to any other company, having a sales force of 34 is tiny; we did that by design. We could have easily raised $10 million in capital and hired 25 sales reps, and there are companies that do that. I think we took a more conservative approach of taking this year to really study the market and study the interaction with distributors so that we can really make sure that when we hire a person, we have a sort of game book for them to step into, and how they interact with distributors and how they interact with customers so that they can be most effective. At the end of the day, every sales rep has an ROI on their back, if you will, and we want to make sure that we hit that; we have all had experience in the past where that has not happened. Yes, I understand. Your point is well taken, and we certainly are not happy with the sales growth. But I think, as a company trying to balance shareholder value through dilution of additional capital versus growth, we made the decision to take this year to really study that. Next year, now that we have the cash reserves and we do not have to raise $10 million and dilute shareholders, we can do this properly. Does that answer your question?
Not quite. In part. I don't believe I was being-
All right.
My question isn't why you aren't putting a lot more in. What I'm wondering is why you're putting in that much, since I would have thought that the existing sales force, with the experience they've built up and the distributor relationships that are a bit more seasoned than they were a year ago, could deliver a certain amount of growth with no extra sales people, close to what you've laid out for Q4 of next year in terms of run rate. It surprises me to hear that run rate you mentioned alongside a plan to double the sales force. For me, it just doesn't compute.
Well, I understand your point. I think the timeline of results has to be factored in. As I said, and as you've observed, it takes on average between nine and 12 months from the first conversation with the customer to go live. If you consider our sales team that was hired at the beginning of the year, by the time they've got their training boots and are ready to go and truly start making an impact, that's the middle of 2026, which means it's unlikely they'll even see revenue coming from there until the beginning of 2027. Following that logic, hiring people throughout 2027 will produce results in 2028. But the aim is to kind of raise the level of the rate of growth.
All right, understood. Fine, I'm set. Appreciate it.
Thank you for asking.
Hi Ilan. That was a strong quarter. It is exciting to watch the progress and a few of those bold goals you have put forward. My focus is on that $10 million product sales run rate as we exit 2027. I am simply wondering how the bridge works, particularly since ramping new reps takes time and you are currently in the middle of trying to bring salespeople on board. Could you walk us through it a bit, maybe how much comes from customer conversations already in motion versus a gap you still need to close between now and Q4 2027?
Yes. Thank you, Daniel. Looking at our pipeline as it stands, converting half of it gets us there; we have a solid set of customers at different stages of talks and onboarding, and so on; and I have said this all along, and I dislike sounding like a scratched record that keeps complaining, but it is really difficult once you begin with a customer to predict exactly when that first order will arrive. Still, with the pipeline we have now, and that is the reason we feel confident enough to offer guidance on a number for the first time, we think we will reach it. And clearly, our sales team is not idle. That pipeline keeps expanding. We are fairly confident we can exceed the figures we have given and, across the year, see a steady acceleration toward hitting that run rate.
That's great. It sounds like a much bigger pipeline than you've had before, if half of it gets you to that run rate. Has the pipeline been growing fairly steadily as you've brought on reps? Or maybe part of that also comes back to nailing the distributor recipe. Perhaps you could give an update on that.
Yeah, it's a bit of both. Obviously, our sales team doesn't just sit quietly and twiddle their thumbs. So they're working, doing a great job interacting with distributors and getting customers to the qualification point where they actually become part of the pipeline. So the pipeline is a number that keeps growing for us. Again, part of the goal of adding sales reps, the sales team, is to speed up that pipeline and get that pipeline converted. If we look at this quarter, we grew by $100,000, right? That's nothing. We want to see an increase of a quarter million dollars a quarter and even half a million dollars a quarter, so that we can really grow this thing and capture more market share.
Great. One more from me. If we go back to Pathology Services and that $30 million run rate goal, it seems to me that revenue growth in Pathology Services has decelerated across the last couple of quarters, and it looks like perhaps you're expecting somewhat of a pickup. Could you give us a little detail on what might drive that? Would it be new customers, new products? What is going to drive growth from now through the end of 2027 on the pathology side?
Yeah, thank you. Great question. I think two factors are at play. First is definitely new customers, and we are in fact broadening the connection between our product customers and our Pathology Services business; we have actually seen a fair amount of success with customers on the product side whom we have actually managed to bring in to generate some pathology revenue. That is one area; we will probably add one or two more reps on the pathology side as well. I think in the end it also comes down to management attention. This year we have been really focused on the product side and everything we discussed about working out the recipe, really building a strong team, building the marketing backbone for this. I think next year this will let us grow the team, and it will also let us really put a little bit of our efforts on the pathology side of the business too, and that should lead to more customers as well. There is not really any change to any products. The services side is pretty standard when it comes to the analysis we perform for patient samples that come in. That stays the same. Hopefully that answered your question.
Understood. Thanks. That's everything from me at this point.
Thanks, Daniel.
Appreciate everyone being here. I hope each of you has a wonderful holiday season, and we'll catch up with you next year. Enjoy your evening.
Thank you. That brings us to the end of today's conference call, ladies and gentlemen. We appreciate everyone for joining. You may disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Precipio, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Precipio, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.